CG Oncology (NASDAQ:CGON) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $75.00 target price on the stock.

CGON has been the topic of a number of other reports. Roth Capital raised shares of CG Oncology to a strong-buy rating in a research note on Tuesday, August 27th. Roth Mkm assumed coverage on CG Oncology in a report on Tuesday, August 27th. They set a buy rating and a $65.00 target price for the company. Finally, Bank of America assumed coverage on CG Oncology in a research note on Friday, June 28th. They issued a buy rating and a $65.00 price target on the stock. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average price target of $64.17.

CG Oncology Trading Up 2.0 %

Shares of CGON stock opened at $37.75 on Tuesday. CG Oncology has a 12-month low of $25.77 and a 12-month high of $50.23. The business’s 50 day moving average is $34.93 and its two-hundred day moving average is $35.40.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.14. The company had revenue of $0.11 million during the quarter. On average, equities analysts predict that CG Oncology will post -1.47 earnings per share for the current year.

Insider Buying and Selling

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total value of $23,000,088.80. Following the completion of the sale, the director now directly owns 586,982 shares of the company’s stock, valued at approximately $20,755,683.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Trading of CG Oncology

Several institutional investors have recently made changes to their positions in CGON. Ameritas Investment Partners Inc. acquired a new stake in CG Oncology during the first quarter worth $102,000. California State Teachers Retirement System purchased a new stake in CG Oncology in the 1st quarter valued at about $103,000. Profund Advisors LLC acquired a new position in CG Oncology in the second quarter valued at about $300,000. BNP Paribas Financial Markets purchased a new position in CG Oncology during the first quarter worth about $492,000. Finally, Capstone Investment Advisors LLC acquired a new stake in shares of CG Oncology during the first quarter valued at about $806,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.